Good evening :)
$
₹
P

Perspective Therapeutics Inc.

CATX

AMEX
P

Perspective Therapeutics Inc.

CATX

AMEX
$0.835.65% (+0.04)
$
₹
$0.835.65% (+0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Micro Cap

With a market cap of $99.3M the stock is ranked 4661

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.36
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.33
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 14 analysts reports

Buy
13 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+1114.82%

Earnings Growth

+29.66%

Rev. Growth

-66.18%

See Detailed Forecast

Company Profile

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
42.94
42.94
1Y Return
7.25%
7.25%
Buy Reco %
82.14
82.14
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
58.29
58.29
1Y Return
12.11%
12.11%
Buy Reco %
76.47
76.47
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.89
38.89
1Y Return
10.7%
10.7%
Buy Reco %
83.33
83.33
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
25.78
25.78
1Y Return
15.97%
15.97%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
36.17
36.17
1Y Return
6.31%
6.31%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 1114.82% growth, versus a trailing 3-year CAGR of -30.57%.

2026
Current$0.87Baseline
Analyst Target - 1 year
Target$10.57+1114.82%

All values in $

202220232024202520262027$3.49$6.21$8.92Target+1114.82%
2026
Current$0.87Baseline
Analyst Target - 1 year
Target$10.57+1114.82%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0.88Baseline
Forecast for Dec 2026
High$1+13.12%
Average$0.29-66.18%
Low$0-100%

All values in $ Million

202220232024202520265.417.101.431.450.88Low-100%Average-66.18%High+13.12%
2025
Current$0.88Baseline
Forecast for Dec 2026
High$1+13.12%
Average$0.29-66.18%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.41Baseline
Forecast for Dec 2026
High$-0.83+40.96%
Average$-0.99+29.66%
Low$-1.27+9.66%

All values in $

20222023202420252026-0.16-0.9-1.16-1.41Low+9.66%Average+29.66%High+40.96%
2025
Current$-1.41Baseline
Forecast for Dec 2026
High$-0.83+40.96%
Average$-0.99+29.66%
Low$-1.27+9.66%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.2
-25.9
0
-37.4
0
-26.1
0
-26.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0.270.320.360.230.360.290.200.040.070.08
Net Income-10.35-12.28-15.12-40.16-15.12-21.48-25.96-37.49-26.18-26.78
Net Profit Margin-3752.17%-3779.69%-4098.10%-17166.23%-4098.10%-7408.62%-12425.35%-87186.04%-34459.21%-33069.13%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Perspective Therapeutics Inc. -0.36-
Abbott Laboratories42.943.701.56
Intuitive Surgical Inc58.299.742.04
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CATX with any stock or ETF
Compare CATX with any stock or ETF
Comparing from
CATX
ABT
ISRG
Loading...

Frequently asked questions

  1. Perspective Therapeutics Inc. (CATX) share price today is $0.83 as of November 6, 2026 at 10:16 PM IST. The stock touched a day high of $0.90 and a day low of $0.80.

  2. Perspective Therapeutics Inc. stock trades on AMEX under the ticker symbol CATX.

  3. Perspective Therapeutics Inc.'s market capitalization is $99.33M as of November 6, 2026 at 10:16 PM IST.

  4. Perspective Therapeutics Inc.'s price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Perspective Therapeutics Inc.'s price-to-book (P/B) ratio is 0.36 as of November 6, 2026.

  6. Yes, You can buy Perspective Therapeutics Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Perspective Therapeutics Inc. shares in three steps: 1. Search Perspective Therapeutics Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Perspective Therapeutics Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Perspective Therapeutics Inc. (CATX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 12.0048 shares at the current price of $0.83.

Loading...